Sanofi (SNY) and Dren Bio, a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has ...

Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...

Addressing his maiden public event, Pandey, who took charge as the Sebi chairman on March 1, said this is essential from the point of view of transparency and added that such moves will help the ...

The festival posted on their Instagram Story this evening a simple video clip of a phoenix rising from the flames and turning into the Worthy Farm festival’s logo. ‘Glastonbury lineup rumored ...

South Africa's competition watchdog probes Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market South Africa’s competition watchdog is investigating ...

Here’s the plain truth: ACIP, made up of pediatricians, public health specialists, and parents, is the gold standard for open, transparent ... the season,” wrote Sanofi in a statement to ...

The Santa Fe sheriff said the 95-year-old actor’s last pacemaker “event” was on Feb. 17 and that may have been “his last day of life.” By Clarissa-Jan Lim Authorities say they believe ...

On February 25, 2025, President Donald J. Trump signed an executive order aimed at enhancing healthcare price transparency and empowering patients with clear, accurate, and actionable pricing ...

South African farmers are expected to harvest 8% more maize in the 2024/2025 season compared with the previous one, the government's Crop Estimates Committee (CEC) said on Thursday. The CEC's first ...

Byrd also said noncompliance flourished due to the administration's lack of transparency with the school board and the public. The state auditor's office reviewed 37.7 million in TPS expenditures ...

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.